BTIG Research Reiterates Buy Rating for Haemonetics (NYSE:HAE)

Posted by on Jun 17th, 2026

Haemonetics (NYSE:HAE – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a note issued to investors on Wednesday,Benzinga reports. They presently have a $84.00 price target on the medical instruments supplier’s stock. BTIG Research’s price objective indicates a potential upside of 12.90% from the company’s previous close.

HAE has been the subject of several other research reports. JPMorgan Chase & Co. lowered their price objective on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Mizuho lifted their price objective on shares of Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research note on Monday. Barrington Research lowered their price objective on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $72.00 to $80.00 in a research report on Friday, May 22nd. Finally, Robert W. Baird set a $67.00 price target on shares of Haemonetics in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and an average price target of $78.33.

Check Out Our Latest Stock Analysis on Haemonetics

Haemonetics Stock Performance

Shares of HAE stock opened at $74.40 on Wednesday. The firm has a 50 day moving average of $63.02 and a 200-day moving average of $67.20. The company has a market cap of $3.38 billion, a price-to-earnings ratio of 36.83, a price-to-earnings-growth ratio of 1.55 and a beta of 0.56. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32.

Haemonetics (NYSE:HAE – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. The company had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. Haemonetics’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, equities analysts forecast that Haemonetics will post 5.22 earnings per share for the current year.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Central Pacific Bank Trust Division boosted its holdings in shares of Haemonetics by 2.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock worth $713,000 after buying an additional 188 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Haemonetics by 12.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 211 shares during the last quarter. Quantinno Capital Management LP boosted its holdings in shares of Haemonetics by 9.0% in the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after buying an additional 289 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Haemonetics by 110.9% in the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 306 shares during the last quarter. Finally, Cardinal Capital Management boosted its holdings in shares of Haemonetics by 1.5% in the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock worth $1,799,000 after buying an additional 321 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

(Get Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Featured Stories

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.